Who is sponsoring NCT05150509?

NCT05150509 is sponsored by DR. MALA KHAN.

What drugs are being tested in NCT05150509?

Interventions in NCT05150509: Oral Squamous Cell Carcinoma.

What condition does NCT05150509 study?

NCT05150509 studies Oral Squamous Cell Carcinoma.

Is NCT05150509 still recruiting?

NCT05150509 is currently status unknown. Last updated 22 February 2022.

Last reviewed 2022-02-22 · How we verify

NCT05150509: OSCC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Association of Salivary Amino Acid Level With OSCC Identified By Liquid Chromatography Mass Spectroscopy

Status unknown Last updated 22 February 2022

What this trial tests

trial testing Oral Squamous Cell Carcinoma in Oral Squamous Cell Carcinoma in 110 participants. Status unknown.

Timeline

15 December 2020

Primary endpoint
20 March 2022

30 March 2022

Quick facts

Lead sponsor	DR. MALA KHAN
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	110
Start date	15 December 2020
Primary completion	20 March 2022
Estimated completion	30 March 2022
Sites	2 locations across Bangladesh

Drugs / interventions tested

Oral Squamous Cell Carcinoma

Conditions studied

Oral Squamous Cell Carcinoma — all drugs for Oral Squamous Cell Carcinoma →

Sponsor

DR. MALA KHAN

Who can join

Eligibility, any sex, with Oral Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Oral Squamous Cell Carcinoma (OSCC) is the most common oral malignancy worldwide. The prognosis of the OSCC patient is not significant despite the modern treatment facilities. Late presentation is one of the most crucial cause of this and for that reason, the importance of early diagnosis of OSCC should be the main concern. Till now, incisional biopsy followed by histopathological examination is the gold standard for diagnosis of oral cancer. The aim of the present study is to find out the association of salivary amino acid levels with oral squamous cell carcinoma, whether the levels are increased or decreased in the patient suffering from OSCC. This might be helpful for early diagnosis of oral cancer and better prognosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Liquid Biopsy in Head and Neck Cancer: Current Evidence and Future Perspective on Squamous Cell, Salivary Gland, Paranasal Sinus and Nasopharyngeal Cancers.
Cabezas-Camarero S, Pérez-Segura P. · · 2022 · cited 12× · PMID 35740523 · DOI 10.3390/cancers14122858

Verify or expand the search:

Other recruiting trials for Oral Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07063212 — A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) · Phase 2 · recruiting
NCT06627270 — Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer · Phase 2 · recruiting
NCT06055868 — People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity · recruiting
NCT06321003 — SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography · recruiting
NCT06258811 — Neoadjuvant Immunochemotherapy for LAOSCC · Phase 3 · recruiting

Other DR. MALA KHAN trials

Trials by the same sponsor.

NCT05190016 — Efficacy of a Multiplex BangasureTM RT-PCR Kit for the Detection of COVID-19 · completed
NCT04872686 — Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx · Phase 3 · completed
NCT04549376 — Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05150509 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by DR. MALA KHAN
Last refreshed: 22 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05150509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing